Status:
RECRUITING
Prevention of Age-associated Cardiac and Vascular Dysfunction Using Avmacol ES
Lead Sponsor:
Texas Tech University Health Sciences Center
Conditions:
Diastolic Dysfunction
Systolic Dysfunction
Eligibility:
All Genders
60-80 years
Phase:
PHASE1
PHASE2
Brief Summary
Our local IRB approved clinical studies seeking proof of principle for the hypothesis that SFN can be safely administered to humans at doses sufficient to protect age-associated cardiac dysfunctions. ...
Detailed Description
Study Design: We intend to include 200 individuals (100 men and 100 women, ≥60 years), with a diagnosis of heart failure with preserved ejection fraction (HFpEF) who are able to walk at least 500 feet...
Eligibility Criteria
Inclusion
- Age \> 60 years
- Diagnosis of HFpEF (HF symptoms with a normal EF (\>/=50 %)
- Ability to walk more than 500 feet (by self-report)
- Willing to avoid taking all over the counter antioxidant phytochemical supplements (vegetable or fruit-containing supplement pills) during the study
Exclusion
- Inability to provide informed consent
- Diagnosis of active cancer
- Inability to read and understand the SF-36 in English
- Participants using over the counter antioxidant supplements
- Participants with pulmonary or other issues which restrict walking capacity
- On oxygen therapy
Key Trial Info
Start Date :
July 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 30 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT05408559
Start Date
July 1 2022
End Date
July 30 2026
Last Update
November 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Texas Tech University Health Sciences Center (TTUHSC)
Lubbock, Texas, United States, 79430